AKT1 and hepatocellular carcinoma: FBXO22 targets the ribosomal protein S5 (RPS5)/AKT/hypoxia inducible factor-1α (HIF-1α)/vascular endothelial growth factor A (VEGF-A) axis, leading to enhancement of angiogenesis and metastasis in HCC (40).